Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes
Journal of Diabetes Investigation · 2025
DOI: 10.1111/jdi.14415 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Qiumei Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glycemic Control, Insulin. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi China Investment Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To evaluate characteristics and glycemic outcomes in individuals with type 2 diabetes using injectable therapies in real‐world clinical practice in Tianjin, China. Materials and methods Data from inpatients and outpatients receiving injectable therapies between January 2015 and December 2019 were collected from the Tianjin regional electronic medical records and retrospectively analyzed. Seven cohorts were identified, including individuals initiating injectable therapies (premixed insulin [ n = 4,687], basal insulin [4,177], or glucagon‐like peptide‐1 receptor agonists [541]) or switching injectable therapies (premixed insulin to basal insulin [1,298], basal insulin to premixed insulin [1,457], basal insulin to basal + bolus insulin [1,772], or glucagon‐like peptide‐1 receptor agonists to basal insulin ± glucagon‐like peptide‐1 receptor agonists [82]).
Results
In participants initiating therapy, glycated hemoglobin and fasting plasma glucose were highest in the basal insulin cohort, while among participants switching therapy, the highest values were in the basal insulin ± glucagon‐like peptide‐1 receptor agonists cohort. Initiating therapy with premixed or basal insulin and switching from basal insulin to basal + bolus insulin improved glycemic control over 12 months. A mean delay in initiating therapy of up to 13 months after oral glucose‐lowering drug failure was observed, with 60% having a delay of >6 months. This delay was associated with a lower proportion achieving glycemic control 3 months after initiation.
Conclusions
Effectiveness was not observed at all time points in all cohorts, suggesting some treatments were not used in the appropriate population. Delays in initiating injectable therapies were observed and were associated with poor glycemic control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
- Sanofi Investment Co., Ltd., Shanghai, China.
ORCID-Profile: Liming Chen
Förderung
- Sanofi China Investment Company
Zitieren
APA
Zhang, Q., Fan, Y., Liu, X., Zhang, M., Zhang, J., Du, Q., Kang, L., & Chen, L. (2025). Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14415
Vancouver
Zhang Q, Fan Y, Liu X, Zhang M, Zhang J, Du Q, et al. Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.14415
BibTeX
@article{Zhang2025,
author = {Zhang, Qiumei and Fan, Yaqing and Liu, Xixi and Zhang, Minlu and Zhang, Jiewen and Du, Qin and Kang, Lei and Chen, Liming},
title = {Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes},
journal = {Journal of Diabetes Investigation},
year = {2025},
doi = {10.1111/jdi.14415}
}
EUVIMED